Structure-activity study of LVV-hemorphin-7: Angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 205-211

  Lee, Joohyung ^a   Mustafa, Tomris ^a   McDowall, Sharon G ^a   Mendelsohn, Frederick A O ^a   Brennan, Michelle ^a   Lew, Rebecca A ^b   Albiston, Anthony L ^a   Chai, Siew Yeen ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINOPEPTIDASE; ANGIOTENSIN 4 RECEPTOR; ANGIOTENSIN RECEPTOR; ENZYME INHIBITOR; INSULIN REGULATED AMINOPEPTIDASE; LEUCYL 2 NAPHTHYLAMIDE; LIGAND; LVV HEMORPHIN 7; PEPTIDE DERIVATIVE; POLYPEPTIDE; SYNTHETIC PEPTIDE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG;

ADRENAL GLAND; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING KINETICS; CARBOXY TERMINAL SEQUENCE; CEREBELLUM; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; SHEEP; STRUCTURE ACTIVITY RELATION;

ALANINE; AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; AMINOPEPTIDASES; CELLS, CULTURED; DRUG INTERACTIONS; GENE DELETION; HEMOGLOBINS; HUMANS; INSULIN; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LIGANDS; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTORS, ANGIOTENSIN; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037380026     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.045492     Document Type: Article

References (23)

1. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, and Chai SY (2001) Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin regulated aminopeptidase. J Biol Chem 276:48623-48626.
2. Braszko JJ, Kupryszewski G, Witczuk B, and Wisniewski K (1988) Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats. Neuroscience 27:777-783.
3. Garreau I, Chansel D, Vandermeersch S, Fruitier I, Piot JM, and Ardaillou R (1998) Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N. Peptides 19:1339-1348.
4. Haberl RL, Decker PJ, and Einhaupl KM (1991) Angiotensin degradation products mediate endothelium-dependent dilation of rabbit brain arterioles. Circ Res 68:1621-1627.
5. Hamilton TA, Handa RK, Harding JW, and Wright JW (2001) A role for the angiotensin IV/AT4 system in mediating natriuresis in the rat. Peptides 22:935-944.
6. Herbst JJ, Ross SA, Scott HM, Bobin SA, Morris NJ, Lienhard GE, and Keller SR (1997) Insulin stimulates cell surface aminopeptidase activity toward vasopressin in adipocytes. Am J Physiol 272:E600-E606.
7. Keller SR, Scott HM, Mastick CC, Aebersold R, and Lienhard GE (1995) Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J Biol Chem 270:23612-23618.
8. Kramar EA, Harding JW, and Wright JW (1997) Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2 and AT4 receptor subtypes. Regul Pept 68:131-138.
9. Kramar EA, Krishnan R, Harding JW, and Wright JW (1998) Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul Pept 74:185-192.
10. Krishnan R, Hanesworth JM, Wright JW, and Harding JW (1999) Structure-binding studies of the adrenal AT4 receptor: analysis of position two- and three-modified angiotensin IV analogs. Peptides 20:915-920.
11. Lee J, Chai SY, Mendelsohn FA, Morris MJ, and Allen AM (2001) Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 40:618-623.
12. Matsumoto H and Mori T (1998) Changes in cystine aminopeptidase (oxytocinase) activity in mouse serum, placenta, uterus and liver during pregnancy or after steroid hormone treatments. Zool Sci 15:111-115.
13. Matsumoto H, Rogi T, Yamashiro K, Kodama S, Tsuruoka N, Hattori A, Takio K, Mizutani S, and Tsujimoto M (2000) Characterization of a recombinant soluble form of human placental leucine aminopeptidase/oxytocinase expressed in Chinese hamster ovary cells. Eur J Biochem 267:46-52.
14. 3H]thymidine incorporation in a neuronal cell line via the AT4 receptor. J Neurochem 73:301-308.
15. Moeller I, Lew RA, Mendelsohn FA, Smith AI, Brennan ME, Tetaz TJ, and Chai SY (1997) The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT4 receptor in the brain. J Neurochem 68:2530-2537.
16. Mustafa T, Chai SY, Mendelsohn FA, Moeller I, and Albiston AL (2001) Characterization of the AT(4) receptor in a human neuroblastoma cell line (SK-N-MC). J Neurochem 76:1679-1687.
17. Sardinia MF, Hanesworth JM, Krebs LT, and Harding JW (1993) AT4 receptor binding characteristics: D-amino acid- and glycine-substituted peptides. Peptides 14:949-954.
18. Sardinia MF, Hanesworth JM, Krishnan F, and Harding JW (1994) AT4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 15:1399-1406.
19. Wade JD, Catimel B, Faux MC, Burgess AW, Nice E, and Otvos L Jr (2001) Structural and biosensor analyses of a synthetic biotinylated peptide probe for the isolation of adenomatous polyposis coli tumor suppressor protein complexes. J Pept Res 58:204-212.
20. Wright JW, Miller-Wing AV, Shaffer MJ, Higginson C, Wright DE, Hanesworth JM, and Harding JW (1993) Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Res Bull 32:497-502.
21. Wright JW, Stubley L, Pederson ES, Kramar EA, Hanesworth JM, and Harding JW (1999) Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 19:3952-3961.
22. Zhang JH, Hanesworth JM, Sardinia MF, Alt JA, Wright JW, and Harding JW (1999) Structural analysis of angiotensin IV receptor (AT4) from selected bovine tissues. J Pharmacol Exp Ther 289:1075-1083.
23. 125I]benzoylphenylalanine-angiotensin IV as a specific photolabel. J Pharmacol Exp Ther 287:416-424.